Efforts were made to obtain as much information as possible, including age at death, sex, PMD, race, clinical brain diagnosis, DLB type (where applicable), α-synuclein and tau Braak stage, and comorbidities; this information is included in Supplementary Material A. This evidence concerns the gene MAPT and Lewy body dementia.